New Disposable Pen Injector Offers Ease Of Use As Well As Customization Options For Use With A Wide Range Of Injectable Drugs

FRANKLIN LAKES, N.J., Oct. 11, 2012 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that the BD Vystra™ Disposable Pen will be showcased at the 2012 Parenteral Drug Association Meeting in Las Vegas. This new self-injection pen has been designed for use with a wide range of therapies that require frequent, low-volume injections or variable dosing.

BD Vystra™ Disposable Pen has been optimized for ease of use, comfort and reliability through rigorous ergonomic and quality assessments to ensure an intuitive, confident user experience. Design features of this pen injector include multi-dosing, simple dose dialing and correction with audible clicks, and large and clear dose markings.

"As more patient care shifts to the out-patient setting, self-injection devices must be able to accommodate the requirements of an ever broader range of drugs and patient profiles," said Krista Thompson, Vice President/Global Leader, BD Medical – Pharmaceutical Systems, Self-Administration Injection Systems Platform. "With the BD Vystra™ Disposable Pen, BD has incorporated several customization options to meet these needs, such as variable or fixed dosing and multiple look-and-feel designs. This ability to customize the device introduces a new level of flexibility for drug manufacturers."

With BD's 115-year heritage and extensive drug delivery experience, the Company is also able to offer pharmaceutical customers full-service support with worldwide reach ranging from pre-clinical to commercialization, along with the reassurance of strong IP protection.

For more information, please visit www.bd.com/vystra.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com. 

Contact: Jamie YaccoPublic Relations(201) 847-4796 [e-mail]

1 2 Next › Last »